Necrotising Enterocolitis Market Research Report Information By End-User (Hospitals, Surgical and Ablation Centers, Research Institute and Others), By Treatment (Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis and Others), By Distribution (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Necrotising Enterocolitis Market Overview

Necrotising Enterocolitis Market Size was valued at USD 4.9 Billion in 2022. The necrotising enterocolitis market industry is projected to grow from USD 5.16 Billion in 2023 to USD 7.933 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.50% during the forecast period (2023 - 2032). Easy access to antibiotic medications and an improving regulatory environment are two key market driver promoting market expansion. Additionally, expanding R&D efforts and government backing, as well as marketers' contributions and the FDA's designation of orphan drugs, present opportunities for market expansion.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Necrotising Enterocolitis Market Trends

• Rising incidence for NEC is driving the market growth

The market CAGR is being driven by the rising occurrence of necrotizing enterocolitis. When the intestinal inflammation known as necrotizing enterocolitis, which typically affects the colon, is not properly treated, it can be fatal. A hole forms in the intestinal wall as a result of necrotizing enterocolitis, which only affects the intestinal lining. Since the break in the intestinal wall allows the normal bacteria in the gut to spill into the belly, other surrounding body organs become infected. A medical emergency has been created by the infection's rapid progression. The most prevalent time for NEC to afflict newborns is 3 to 12 days following birth. Lethargy, fever, apnea, poor tolerance to emotions, bloody stool, stomach redness, and others are among the signs of NEC. Antibiotics, vasopressors, glucocorticoids, and opioid analgesics are some of the most popular treatments for NEC. According to an NCBI publication, NEC is the most common cause of newborn gastrointestinal infection-related death, accounting for 1-3 occurrences per 1000 live births annually in North America. This growing patient population has a variety of symptoms that call for appropriate treatment; as a result, it is anticipated that the market will experience profitable expansion.

The market expansion is predicted to be fueled by the expanded range of treatment options available for NEC. Increasing populations and per capita incomes have changed people's needs, which is fueling the  market's revenue growth. People now prefer more cutting-edge, scientifically complex treatments and pharmaceuticals. The government's improved regulatory framework for the development of new antibiotics and therapies to minimize the effects of necrotizing enterocolitis in newborn babies, as well as the accessibility of treatments and medications for the treatment of necrotizing enterocolitis, are also expected to significantly propel revenue growth of the necrotizing enterocolitis market over the forecast period.

The necrotizing enterocolitis market is anticipated to experience revenue growth as a result of increased government funding for research and initiatives. As this condition is now a matter of public health, governments worldwide do not want newborn babies dying in their nations from a lack of healthcare services. As a result, necrotizing enterocolitis treatment has steadily advanced over the world. For instance, to develop and test new prognostic models for sepsis and necrotizing enterocolitis, the University of Virginia's Centre for Advanced Medical Analytics provides the necessary funding and resources. Thus, driving the necrotising enterocolitis market revenue.

Necrotising Enterocolitis Market Segment Insights

Necrotising Enterocolitis End-User Insights

The necrotising enterocolitis market segmentation, based on end-user includes Hospitals, Surgical and Ablation Centers, Research Institute and Others. The hospitals segment dominated the market. due to an increase in NEC cases and growing knowledge of early detection. In addition, hospitals are now regarded as primary care institutions by the majority of patients, which is expected to substantially increase demand in the near future. Whereas, during the projection period, research institute segment is anticipated to increase at the greatest CAGR. The prevalence of necrotizing enterocolitis is rising, and there are more research institutes than ever before. Because these institutes aids in the early detection of the disease.

Necrotising Enterocolitis Treatment Insights

The necrotising enterocolitis market segmentation, based on treatment includes Total Parenteral Nutrition (TPN), Gastrointestinal Decompression, Antimicrobial Therapy, Antifungal Treatment, Paracentesis and Others. The total parenteral nutrition (TPN) segment dominated the market. Total parenteral nutrition (TPN), which delivers nutrients intravenously, may initially be necessary for infants with NEC. Enteral feeding, or feeding through the digestive tract, is progressively resumed when the condition gets better. Since breast milk has been proved to protect against NEC, it is preferable. Prebiotics or probiotics may occasionally be used to support gut health.

Necrotising Enterocolitis Distribution Insights

The necrotising enterocolitis market segmentation, based on distribution, includes Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. The hospital pharmacy category generated the most income. Necrotizing enterocolitis (NEC) is managed and treated by the hospital pharmacy segment, which supplies drugs such antibiotics and other supportive medicines. The pharmacy department is in charge of locating, preparing, and dispensing the medicines required for treating NEC patients even if there isn't a designated "market" for NEC inside hospital pharmacies.

Figure 1  Necrotising Enterocolitis Market, by Distribution, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Necrotising Enterocolitis Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American necrotising enterocolitis market area will dominate this market because necrotizing enterocolitis is becoming more common and because disease detection technology is advanced. Necrotizing enterocolitis, with 1-3 cases per 1,000 births observed in North America each year, is the leading cause of gastrointestinal infection-related infant death, according to the National Centre for Biotechnology Information (NCBI). The expanding patient base has a variety of symptoms that call for the right care, which is expected to fuel market growth. The North American market is also being driven by an increase in healthcare spending. Over the course of the projected period, these factors are also anticipated to help the region gain market share.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 NECROTISING ENTEROCOLITIS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe necrotising enterocolitis market accounts for the second-largest market share as the majority of the research and development efforts are being made in industrialized nations like France, Germany, Denmark, Belgium, etc., for the creation of a long-lasting remedy for the infection. Additionally, these nations have seen a significant expansion of the necrotizing enterocolitis market as a result of the quick advancements in technology. Further, the German necrotising enterocolitis market held the largest market share, and the UK necrotising enterocolitis market was the fastest growing market in the European region

The Asia-Pacific Necrotising enterocolitis Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous nations, including China, Japan, Korea, and India, are thought to produce the majority of the market's earnings from necrotizing enterocolitis. Data on necrotizing enterocolitis show that the majority of people in these nations are infants and newborns, who are more prone to developing necrotizing enterocolitis. Additionally, the region's healthcare market is experiencing revenue growth as a result of the shift in people's health consciousness and the modernization of healthcare facilities. Moreover, China’s necrotising enterocolitis market held the largest market share, and the Indian necrotising enterocolitis market was the fastest growing market in the Asia-Pacific region.

Necrotising Enterocolitis Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the necrotising enterocolitis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, necrotising enterocolitis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  necrotising enterocolitis industry to benefit clients and increase the market sector. In recent years, the necrotising enterocolitis industry has offered some of the most significant advantages to market. Major players in the necrotising enterocolitis market attempting to increase market demand by investing in research and development operations include Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson, and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company, Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), and GlaxoSmithKline Plc (UK).

Bristol-Myers Squibb Co. (BMS) is a specialist biopharmaceutical business that develops, manufactures, distributes, and sells drugs and related medical supplies to people with serious conditions. Cancer, cardiovascular, immunology, and fibrotic therapeutic projects are its main areas of interest. The business provides its goods to wholesalers, retail pharmacies, health care workers, hospitals, and governmental organisations all around the world. Products from BMS are available in the US, Europe, and Japan. The organisation conducts research with a focus on the discovery and development of brand-new medications that treat severe illnesses in regions with a high unmet medical need.

Pharmaceuticals of all kinds are discovered, developed, produced, and sold by Astellas Pharma Inc (Astellas). Marketed treatments for the treatment of a variety of urological disorders, cancer, nephrology, infectious diseases, metabolic diseases, immunodeficiency diseases, and transplantation are included in the company's product portfolio. Its pipeline includes drug candidates for the treatment of various diseases, including acute myeloid leukaemia (AML), urothelial cancer, gastric cancer, gastroesophageal junction cancer, anaemia linked to chronic kidney disease (CKD) in dialysis patients, rheumatoid arthritis, and non-dialysis patients.

Key Companies in the necrotising enterocolitis market include

• Abbott Laboratories Inc. (U.S.)


• Astellas Pharma Inc. (Japan)


• Bayer HealthCare AG (Germany)


• Becton, Dickinson, and Company (BD) (U.S.)


• Bristol-Myers Squibb Company (U.S.)


• Daiichi Sankyo Company, Ltd. (Japan)


• Eli Lilly and Co. (U.S.)


• Enzon Pharmaceuticals, Inc. (U.S.)


• Hoffmann-La Roche Ltd (Switzerland)


• GI Supply (U.S.)


• GlaxoSmithKline Plc (UK)

Necrotising Enterocolitis Industry Developments

June 2022 The Exclusive Human Milk Diet, which includes Prolacta Bioscience products (Prolacta's EHMD), has been used in the neonatal intensive care unit (NICU) with the first evidence-based feeding approach just being introduced by Prolacta Bioscience. The EHMD Protocol TM from Prolacta is the first nutritional recommendation for the use of the company's human milk-based nutritional products, and it addresses the nutritional issues of delayed and inadequate sustenance presented by low birth weight preterm newborns.

February 2021 Through the enrollment of 300 preterm children in the ongoing clinical Phase III research of IBP-9414, Infant Bacterial Therapeutics (IBT) achieved a significant milestone. In order to enroll children with extremely low birth weights, this means that a safety investigation of these newborns will be carried out. It is anticipated that this will significantly increase recruitment rates. It is anticipated that the investigation will be finished by November 2022. The expansion of the  market may be significantly impacted by this study's success.

March 2018 Prometic Life Sciences Inc.'s Inter-Alpha-Inhibitor-Proteins, which is anticipated to be a major medication for the treatment of necrotizing enterocolitis, received approval from the U.S. Food and Drug Administration (FDA) department.

Necrotising Enterocolitis Market Segmentation

Necrotising Enterocolitis End-User Outlook (USD Billion, 2018-2032)

• Hospitals


• Surgical and Ablation Centers


• Research Institute


• Others

Necrotising Enterocolitis Treatment Outlook (USD Billion, 2018-2032)

• Total Parenteral Nutrition (TPN)


• Gastrointestinal Decompression


• Antimicrobial Therapy


• Antifungal Treatment


• Paracentesis


• Others

Necrotising Enterocolitis Distribution Outlook (USD Billion, 2018-2032)

• Direct Tender


• Hospital Pharmacy


• Retail Pharmacy


• Online Pharmacy


• Others

Necrotising Enterocolitis Regional Outlook (USD Billion, 2018-2032)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America